The BRAFV600E mutation in papillary thyroid microcarcinoma: Does the mutation have an impact on clinical outcome?

Clinical Endocrinology

Volumn 80, Issue 6, 2014, Pages 899-904

  Walczyk, Agnieszka ^a   Kowalska, Aldona ^a   Kowalik, Artur ^a   Sygut, Jacek ^a   Wypiõrkiewicz, Elzbieta ^a   Chodurska, Renata ^a   Piȩciak, Liliana ^a   Gõźdź, Stanisław ^a,b  

^a Holycross Cancer Centre   (Poland)

^b JAN KOCHANOWSKI UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALLELE; ARTICLE; BRAF GENE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DNA EXTRACTION; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN TISSUE; INCIDENCE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; ONCOGENE; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SURVIVAL RATE; THYROID PAPILLARY CARCINOMA; AGED; CODON; GENETICS; METASTASIS; MIDDLE AGED; MUTATION; PAPILLARY CARCINOMA; PROGNOSIS; RETROSPECTIVE STUDY; THYROID TUMOR; TREATMENT OUTCOME;

B RAF KINASE; BRAF PROTEIN, HUMAN; CODON;

AGED; ALLELES; CARCINOMA, PAPILLARY; CODON; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INCIDENCE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 84899587412     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12386     Document Type: Article

References (25)

1. Davies, H., Bignell, G.R., Cox, C., et al,. (2002) Mutation of the BRAF gene in human cancer. Nature, 417, 949-954.
2. Xing, M., (2005) BRAF mutation in thyroid cancer. Endocrine-Related Cancer, 12, 245-262.
3. Kim, T.H., Park, Y.J., Lim, J.A., et al,. (2012) The association of the BRAF V600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer, 118, 1764-1773.
4. Nam, J.K., Jung, C.K., Song, B.J., et al,. (2012) Is the BRAF V600E mutation useful as a predictor of preoperative risk in papillary thyroid cancer? The American Journal of Surgery, 203, 436-441.
5. Kim, T.Y., Kim, W.B., Song, J.Y., et al,. (2005) The BRAF mutation is not associated with poor prognosis factor in Korean patients with conventional papillary thyroid microcarcinoma. Clinical Endocrinology, 63, 588-593.
6. Cohen, Y., Xing, M., Mambo, E., et al,. (2003) BRAF mutation in papillary thyroid carcinoma. Journal of the National Cancer Institute, 95, 625-627.
7. Xing, M., (2012) BRAF V600E mutation and papillary thyroid cancer: chicken or egg? Journal of Clinical Endocrinology and Metabolism, 97, 2295-2298.
8. Kebebew, E., Weng, J., Bauer, J., et al,. (2007) The prevalence and prognostic value of BRAF mutation in thyroid cancer. Annals of Surgery, 246, 466-471.
9. Lupi, C., Giannini, R., Ugolini, C., et al,. (2007) Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism, 92, 4085-4090.
10. Ito, Y., Yoshida, H., Maruo, R., et al,. (2009) BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocrine Journal, 56, 89-97.
11. Tang, K.T., &, Lee, C.H., (2010) BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications. Journal of the Chinese Medical Association, 73, 113-125.
12. Yu, X.M., Wan, Y., Sippel, R.S., et al,. (2011) Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18445 cases. Annals of Surgery, 254, 653-660.
13. Riemann, B., &, Schober, O., (2009) Therapeutic strategy of papillary microcarcinoma of the thyroid gland: a nuclear medicine perspective. Minerva Endocrinologica, 34, 81-87.
14. McLeod, D.S.A., Sawka, A.M., &, Cooper, D.S., (2013) Controversies in primary treatment of low-risk papillary thyroid cancer. The Lancet, 381, 1046-1057.
15. Nikiforova, M.N., Kimura, E.T., Gandhi, M., et al,. (2003) BRAF mutation a in thyroid tumors are restricted to papillary carcinoma and anaplastic or poorly differentiated thyroid carcinoma arising from papillary carcinoma. Journal of Clinical Endocrinology and Metabolism, 88, 5399-5404.
16. Kim, S.W., Lee, J.I., Kim, J.W., et al,. (2010) BRAF V600E mutation analysis in fine needle aspiration cytology specimens for evaluation of thyroid nodule: a large series in a BRAFV600E-prevalent population. Journal of Clinical Endocrinology and Metabolism, 95, 3693-3700.
17. Sarne, D., (2012) A piece of the puzzle: what does BRAF mutation status mean in the management of patients with papillary thyroid carcinoma? Journal of Clinical Endocrinology and Metabolism, 97, 3094-3096.
18. Xing, M., (2007) BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocrine Reviews, 28, 742-762.
19. Handkiewicz-Junak, D., Czarniecka, A., &, Jarza̧b, B., (2010) Molecular prognostic markers in papillary and follicular thyroid cancer: current status and future directions. Molecular and Cellular Endocrinology, 322, 8-28.
20. Rodocilo, V., Cabbi, D., Pizzolanti, G., et al,. (2007) BRAF (V600E) mutation and p27(kip1) expression in papillary thyroid carcinomas of the thyroid ≤ 1 cm and their paired lymph node metastases. Cancer, 110, 1218-1226.
21. Virk, R.K., Dyke, A.L., Filkenstein, A., et al,. (2013) BRAF V600E mutation in papillary thyroid microcarcinoma: a genotype-phenotype correlation. Modern Pathology, 26, 62-70.
22. Verburg, A., Luster, M., Cupini, C., et al,. (2013) Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a clinical position statement. Thyroid, 23, 1211-1226.
23. Li, C., Han, P.A., Lee, K.C., et al,. (2013) Does BRAF V600E mutation predict aggressive features in papillary thyroid cancer? Results from four endocrine surgery centres. Journal of Clinical Endocrinology and Metabolism, 98, 3702-3712.
24. Guerra, A., Sapio, M., Marotta, V., et al,. (2012) The primary occurrence of BRAF V600E is a rare clone event in papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism, 97, 517-524.
25. Guerra, A., Fugazzola, L., Marotta, V., et al,. (2012) A high percentage of BRAF V600E allele in papillary thyroid carcinoma predicts a poorer outcome. Journal of Clinical Endocrinology and Metabolism, 97, 2333-2340.